The Remarkable Selectivity of Nirmatrelvir.

Published in: ACS pharmacology & translational science (2022)

The SARS-CoV-2 main protease is among the most attractive targets for the development of therapeutic interventions for COVID-19. Successful candidate agents will not only possess potent on-target activity versus SARS-CoV-2 M pro but also minimal polypharmacology versus human cysteine proteases. This Viewpoint explores the activity profile of the first approved SARS-CoV-2 M pro inhibitor (Nirmatrelvir) versus a panel of cysteine proteases and considers the therapeutic implications of the data.

Keyphrases

sars cov
respiratory syndrome coronavirus
endothelial cells
anti inflammatory
physical activity
electronic health record
fluorescent probe
big data
artificial intelligence
deep learning